{"id":"NCT01084551","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)","officialTitle":"A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/Day to Investigate Superiority to Placebo in Patients With Restless Legs Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2011-09","completion":"2011-09","firstPosted":"2010-03-10","resultsPosted":"2014-06-05","lastUpdate":"2014-06-05"},"enrollment":284,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Restless Legs Syndrome"],"interventions":[{"type":"DRUG","name":"SPM 962","otherNames":[]},{"type":"DRUG","name":"SPM 962","otherNames":[]},{"type":"DRUG","name":"Placebo of SPM 962","otherNames":[]}],"arms":[{"label":"SPM 962 4.5","type":"EXPERIMENTAL"},{"label":"SPM 962 6.75","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the clinical efficacy and safety of SPM962 in patients with restless legs syndrome (RLS) with once-daily repeated doses of 4.5mg and 6.75mg during a 13-week dose-titration and maintenance period. This is a multi-center, randomized, placebo-controlled, double-blind, 3-armed parallel group comparison study.\n\nEfficacy will be determined by investigating the superiority of SPM962 to placebo in terms of the primary efficacy variable, change in International Restless Legs Syndrome Rating Scale (IRLS) total score from baseline to the end of the dose-maintenance period.","primaryOutcome":{"measure":"International Restless Legs Syndrome Rating Scale (IRLS) Total Score","timeFrame":"Baseline, the end of dose-titration/dose-maintenance period (week 13)","effectByArm":[{"arm":"Placebo","deltaMin":-11.6,"sd":8.2},{"arm":"SPM 962 4.5","deltaMin":-14.3,"sd":8.9},{"arm":"SPM 962 6.75","deltaMin":-14.6,"sd":9}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":25},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":["24055212"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":95},"commonTop":["Application Site Reaction","Nausea","Nasopharyngitis","Somnolence","Vomiting"]}}